Eli Lilly and Company

Abbott Laboratories Corporation

Robert William Siegel

Robert John Konrad

Joan D Tyner

David J Hawksworth

Robert N Ziemann

Jonathan Wesley Day

Bryan C Tieman

Bailin Tu

Qing Chai

Oliver Schroeder

Yuewei Qian

Susan E Brophy

Dinesh O Shah

Richard Earl Higgs, Jr

Brian Jeffrey Nickoloff

Suresh M Desai

Larry G Birkenmeyer

Qiaoqiao Ruan

Sergey Y Tetin

Frank C Grenier

Ryan F Workman

Edward T Olejniczak

David Edward Watson

Terry Y Nakagawa

John Harrison Sloan

Nan Jia

Joan D(deceased) Tyner

The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.

Compounds and methods targeting interleukin-19

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

Anti-ANGPTL 3/8 complex antibodies and methods of using the same

Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.

Polynucleotides for preparing ANGPTL 3/8 complexes

Anti-ANGPTL &#x215c; complex antibodies and methods of using the same

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

ANGPTL3/8 complexes and methods of using the same

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.

Anti-glucagon antibodies and uses thereof

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The present invention relates among other things to antibodies that immunospecifically bind to at least one agent of interest (e.g., an immunosuppressive agent), methods for producing such antibodies, and immunoassays that employ said antibodies. Additionally, the present invention also relates to methods for selecting an antibody for use in a diagnostic immunoassay and methods for selecting an antigen for use in a diagnostic immunoassay. The present invention further relates to the improvement of antibody recognition of an active parent drug in the presence of one or more of its major metabolites.

Immunosuppressant binding antibodies and methods of obtaining and using same

Growing community of inventors

Fountaintown, IN, United States of America

Robert William Siegel